Enrollment has just been accomplished for a study in patients with moderate to severe Ulcerative Colitis, a global double-blind, placebo-controlled, parallel group multicenter study designed to evaluate the safety profile of the investigational product.
Our team is currently working towards the completion of this challenging and complex study aimed to enhance treatment methods for the patients.
Pictured: Histopathological image showing moderate ulcerative colitis, by CoRus under CC:BY-SA